San Diego, CA – Agilex Biolabs, Australia’s leading bioanalytical laboratory for global clients conducting preclinical and clinical trials announced at DIA 2019 this week it will analyse more than 60,000 samples in 2019 (June 23-27 San Diego, CA) Booth #2006.
Agilex Biolabs, the only FDA-inspected labs in Australia, offers bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS (7) and Immunoassay (MesoScale, Gyrolab).
CEO Jason Valentine said:
“Our FDA-inspected facilities have more than 40 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC.”
“By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.”
Compliance is key to the Agilex Biolabs success.
“Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.”
For meetings with Agilex Biolabs at DIA please contact us here
About Agilex Biolabs
Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980’s has grown into a business with a global client base.
In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world.
Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA.
Agilex Biolabs is built upon four core values that drive our performance:
- Scientific excellence and technological innovation
- Customer focus
- Data integrity and quality assurance
- Timeliness/speed
